In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Rare disease start-up Harmony raises $270mm in early equity funding

Executive Summary

Concurrent with procuring an exclusive US license to Bioprojet's narcolepsy candidate pitolisant, Harmony Biosciences LLC (developing rare disease therapeutics) announced it raised $270mm in equity financing (assumed to be its Series A round) from 29 investors, including Valor Equity Partners, Fidelity Management & Research, HBM Healthcare Investments, Vivo Capital, venBio Partners, Novo Holdings, and Nan Fung Life Sciences.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies

Advertisement
UsernamePublicRestriction

Register